- Accesswire•11 days agoBiotech Industry Off to a Strong Start in 2017 Latest Reports on Sarepta Therapeutics and Momenta Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / January 9, 2017 / The Biotech Industry has had a strong start to the year after a rocky 2016. The iShares NASDAQ Biotechnology Index ETF ( IBB ) and the SPDR S&P Biotech ETF ...
- Zacks•14 days ago
Momenta Pharmaceuticals, Inc. (MNTA) entered into an exclusive research collaboration and worldwide license agreement with CSL Limited.
- American City Business Journals•14 days ago
Shares of Momenta Pharmaceuticals soared to their highest point in more than a year on Friday after the Cambridge biotech announced a drug development deal worth at least $50 million. Momenta (MNTA) said it had reached a deal with Australia-based CSL Limited to develop autoimmune disease treatments, including one called M230 that is expected to begin clinical trials this year.
MNTA : Summary for Momenta Pharmaceuticals, Inc. - Yahoo Finance
Momenta Pharmaceuticals, Inc. (MNTA)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||13.40 x 200|
|Day's Range||14.57 - 15.00|
|52 Week Range||7.86 - 17.25|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-9.67|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|